JITC's Reading List

JITC HomeAbout JITCRecent ArticlesJITC Editorial Board Highly Accessed ArticlesJITC Digest Follow JITC on X

April 2024 JITC Reading List: Dr. Marcela Maus

By JITC Publications posted 12 days ago
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Immune Cell Therapies and Immune Cell Engineering Section Editor Dr. Marcela Maus . “A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells” by Victor Tieu et al Cell (2024) Summary : CRISPR technologies have begun to revolutionize T cell ...
0 comments

March 2024 JITC Reading List: Dr. Jason Luke

By JITC Publications posted 03-18-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translational Cancer Immunotherapy co-Section Editor Dr. Jason Luke . “Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer” by Memon et al Cancer Cell (2024) Summary: Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about ...
0 comments

February 2024 JITC Reading List: Dr. Sebastian Kobold

By JITC Publications posted 02-15-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Case Reports Section Editor Dr. Sebastian Kobold. “T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy” by Ghilardi et al Nat Med (2024) Abstract: We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin ...
0 comments

January 2024 JITC Reading List: Dr. Robert L. Ferris

By JITC Publications posted 01-16-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Guidelines and Consensus Statements Section Editor Dr. Robert L. Ferris . “Lung tumor–infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response” by Dykema et al Sci Immunol . (2023) Abstract : Regulatory T cells (T reg ) are conventionally viewed as suppressors ...
0 comments

December 2023 JITC Reading List: Dr. Alexandra Snyder

By JITC Publications posted 12-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Immunotherapy Biomarker's co-Section Editor Dr. Alexandra Synder . “The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients” by Freidrich et al Cancer Cell (2023) Abstract : Bispecific T cell engagers (TCEs) have shown promise in the treatment of various ...
0 comments

November 2023 JITC Reading List: Dr. Praveen Bommareddy

By JITC Publications posted 11-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Praveen Bommareddy . Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial by Routy et al Nature Medicine (2023) Combination therapy with immune checkpoint inhibitors has revolutionized treatment for melanoma, but there is still a significant ...
0 comments

October 2023 JITC Reading List: Dr. Kristin Anderson

By JITC Publications posted 10-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Kristin Anderson . “An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment” by DePeaux et al J Exp Med (2023) Abstract : While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments ...
0 comments

September 2023 JITC Reading List: Dr. James L. Gulley

By JITC Publications posted 09-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Interim Editor-in-Chief Dr. James L. Gulley . “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma A Meta-Analysis” by Serritella et al JAMA Oncol. (2023) Abstract: Importance – Although the combination of nivolumab plus ipilimumab has unquestionable benefit over nivolumab monotherapy ...
0 comments

August 2023 JITC Reading List: Dr. Eric Tartour

By JITC Publications posted 08-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Basic Tumor Immunology co-Section Editor Dr. Eric Tartour . “CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers” by Bill et al Science (2023) Abstract: Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering ...
0 comments

July 2023 JITC Reading List: Dr. Sandra Demaria

By JITC Publications posted 07-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Reviews co-Section Editor Dr. Sandra Demaria . “The PD-L1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in HNSCC” by Nieto et al J Natl Cancer Inst. (2023) Abstract: The programmed death receptor 1 (PD-1) and ligand (PD-L1) are validated cancer ...
0 comments

June 2023 JITC Reading List: Dr. Douglas McNeel

By JITC Publications posted 06-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translation co-Section Editor Dr. Douglas McNeel . “Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance” by Dhivya Sridaran et al Nat Commun . (2022) Abstract: Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies ...
0 comments

May 2023 JITC Reading List: Dr. Ignacio Melero

By JITC Publications posted 05-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Immunotherapy Biomarkers co-Section Editor Dr. Ignacio Melero . “Antibodies against endogenous retroviruses promote lung cancer immunotherapy” by Kevin W Ng et al Nature (2023) Abstract: B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid ...
0 comments

April 2023 JITC Reading List: Dr. Sjoerd H. van der Burg

By JITC Publications posted 04-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Interim Deputy Editor-in-Chief Dr. Sjoerd H. van der Burg. “Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction” by Jingya Qiu et al Nature Cancer (2023) Loss of interferon gamma (IFNy) signaling is a canonical mechanism of resistance to PD-1 ...
0 comments

March 2023 JITC Reading List: Dr. Christian Capitini

By JITC Publications posted 03-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Commentary/Editorials Section Editor Dr. Christian Capitini . “T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis” by Daria Briukhovetska et al Immunity (2023) IL-22-producing helper (T h ) cells are associated with poor prognosis in breast and lung ...
0 comments

February 2023 JITC Reading List: Dr. Cornelis J.M. Melief

By JITC Publications posted 02-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Basic Tumor Immunology co-Section Editor Dr. Cornelis J.M. Melief . “Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma” by Jason A. Chesney et al JCO (2023) Jason A. Chesney et al report a phase III, double-blinded, ...
0 comments

January 2023 JITC Reading List: Dr. Sebastian Kobold

By JITC Publications posted 01-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Case Reports Section Editor Dr. Sebastian Kobold. JITC’S READING LIST SUMMARIES – JANUARY 2023 “Glofitamab for relapsed or refractory diffuse large B cell lymphoma” by Michael J Dickinson et al NEJM (2022) Prognosis is poor for patients with diffuse large B cell lymphoma (DLBCL) who have received at least two prior lines ...
0 comments

December 2022 JITC Reading List: Dr. Robert L. Ferris

By JITC Publications posted 12-01-2022
This month's featured editor is Dr. Robert L. Ferris, Section Editor for the Guidelines and Consensus Statements section. “LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation” by Clifford Guy et al Nat Immunol (2022) The mechanism by which LAG3 inhibits T cell-mediated anti-cancer immunity is not well understood. Through elegant biophysical experiments, Clifford Guy et al ...
0 comments

November 2022 JITC Reading List: Dr. Praveen Bommareddy

By JITC Publications posted 11-01-2022
This month's featured editor is a JITC Social Media Editor, Dr. Praveen K. Bommareddy. “ Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial – ECOG-ACRIN EA6134” by Michael B. Atkins et al J Clin Oncol (2022) Two highly effective first-line combination therapies are available for patients with BRAF V600-mutated melanoma: targeted therapy ...
0 comments

October 2022 JITC Reading List: Dr. Pedro J. Romero

By JITC Publications posted 10-01-2022
This month's featured editor is Dr. Pedro J. Romero, Editor-in-Chief. “PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells” by Laura Codarri Deak et al Nature (2022) Interleukin (IL)-2 is an essential cytokine and growth factor for T cell expansion and differentiation. While IL-2 has been utilized as a cancer immunotherapy, the presence of the alpha chain of the IL-2 receptor (IL-2R-α, CD25) on non-tumor ...
0 comments

September 2022 JITC Reading List: Dr. James L. Gulley

By JITC Publications posted 09-01-2022
This month's featured editor is Dr. James Gulley, JITC Deputy Editor-in-Chief. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer” by Andrea Cercek et al NEJM (2022) Mismatch repair deficient (dMMR) colorectal cancer is responsive to anti-PD-1-based immune checkpoint inhibition (ICI) in the metastatic setting, and Andrea Cercek and colleagues hypothesized that treatment with the anti-PD-1 monoclonal antibody ...
0 comments